Material
T he transcription factor NF-B and the MAPK JNK are both activated downstream of Ag receptors, and together regulate the activation, proliferation, apoptosis, survival, and differentiation of lymphocytes (1, 2) . In Ag receptor signaling, both NF-B and JNK share requirements for molecules involved in the proximal tyrosine phosphorylation cascade leading to phospholipase C␥ activation. They also both require protein kinase C (PKC) 3 -dependent activation of caspase recruitment domain (CARD) membrane-associated guanylate kinase (MAGUK) containing protein 1 (CARMA1), as well as the downstream adaptors Bcl-10 and MALT1 (3) . Downstream of MALT1, many of the molecular players required for activation of the classical NF-B pathway have been described, and are shared with other families of membrane-bound receptors. Activation of JNK is less fully understood, but is known to require phosphorylation mediated by MEK4, MEK7, and MEK6 in lymphocytes (1, 4) . Once activated, JNK phosphorylates various downstream substrates, including cJun, to promote activation of the AP-1 transcription factor (5) .
The adaptor protein CARMA1 is required for activation of both of these pathways. CARMA1-deficient cellular and animal models have demonstrated the importance of this protein in immunity (6 -11) . CARMA1-deficient lymphocytes exhibit reduced proliferation, differentiation, and survival to Ag receptor engagement or agonists (PMA/Ionomycin (P/I), as chemical activators of PKCs). At the molecular level, BCR or TCR stimulation of CARMA1-deficient lymphocytes induces normal phosphotyrosine signals, Ca 2ϩ flux, and ERK phosphorylation; however, NF-B and JNK activity remains inactive. Structurally, CARMA1 contains several domains important for the recruitment of signaling proteins as well as for its oligomerization and plasma membrane recruitment (12, 13) . The N-terminal portion of CARMA1 includes both a CARD and a coiled-coil domain, which are required for the recruitment of the adaptor protein Bcl-10 (10, 12-15) and CARMA1 oligomerization (16) , respectively. These domains are linked to a C-terminal region highly related to the MAGUK family of proteins (17) . The MAGUK region contains a PDZ (postsynaptic density 95/disc large/zona occludens 1) domain, a Src homology 3 domain, and a guanylate kinase (GUK)-like domain. The CARD, coiled-coil, Src homology 3, and GUK domains are each required for CARMA1 activity (12, 18) and interact with distinct proteins to coordinate CARMA1 signaling (e.g., CARD with BCL-10, coiled-coil for homodimerization, and so on) (3) .
We and others have demonstrated that CARMA1 activation is controlled by PKC␤ in B cells and PKC in T cells (19, 20) . Activated PKC␤ or PKC phosphorylate a flexible region of CARMA1 linking the coiled-coil and PDZ domains termed the PKC-regulated domain (PRD) (3, 21) . We demonstrated that specific serine residues within the murine PRD (S564, S649, and S657) were phosphorylated by recombinant PKC␤/ isoenzymes in vitro, and mutation of these residues to alanine revealed that both S564 and S657 were required for Ag receptor-induced NF-B activation in Jurkat T cells. In contrast, the S649 residue was apparently not required for the activation of a NF-B reporter gene (20) . Similar results were recently reported for the analogous serine residue (S660) of chicken CARMA1 (22) .
These findings suggested two alternative possibilities with regard to the role for S649: that this residue is not a functionally relevant in vivo phosphorylation site in lymphocytes; or that S649 phosphorylation occurs in vivo, but has a separate role from that of activating CARMA1 signaling. In this report, we demonstrate that, although S657 phosphorylation delivers a positive signal for NF-B and JNK activation, S649 phosphorylation negatively impacts these molecular events in lymphocytes. Functionally, S649 mutation results in a decrease in the survival and growth of reconstituted CARMA1
Ϫ/Ϫ DT40 B cells, compared with wild-type (WT) CARMA1. Using Abs directed to phosphorylated S649 (phospho-S649) and phosphorylated S657 (phospho-S657), we show that CARMA1 is phosphorylated in vivo at both S657 and S649 in response to Ag receptor engagement, yet with markedly different kinetics. Thus, specific phosphorylation of serine residues in the PRD differentially regulates the downstream signaling activity of CARMA1.
Materials and Methods

Cells lines, reagents, and Abs
Chicken B cell lines with genetic deletions of PKC␤ or CARMA1 (PKC␤ Ϫ/Ϫ DT40 and CARMA1 Ϫ/Ϫ DT40) were gifts from T. Kurosaki (RIKEN Research Center for Allergy and Immunology, Kanagawa, Japan) (23); human Ramos B cells, Jurkat T cells, and human embryonic kidney (HEK) 293 fibroblasts were obtained from American Type Culture Collection. Cells were cultured as described (20) . Rottlerin, Ro318425, PMA, and ionomycin were from EMD Biosciences. Abs used were against the following: chicken IgM (Bethyl Labs); myc epitope (9E10; Sigma-Aldrich); human CD28 and IB kinase (IKK)-␥ (BD Biosciences); phospho-ERK, ERK, actin, IB␣, and PKC␤-II (Santa Cruz Biotechnology); phospho-IB␣ and phospho-JNK (Cell Signaling Technology); and human CD3 (OKT3), a gift from Dr. S. Ziegler (Benaroya Research Institute, Seattle, WA). Polyclonal Abs against phospho-S649 and phospho-S657 of murine CARMA1 were generated in rabbits by Open Biosystems using phosphorylated peptides phospho-S649 (LRKF(pS)LERPFR) and phospho-S657 (ERPFRP(pS)VTSG).
Generation of retroviral supernatants and stable cells lines
HEK 293 cells (5 ϫ 10 6 /plate) were transfected using calcium phosphate with 10 g of the retroviral packaging plasmid 10A1 and each of the following cDNAs: myc-CARMA1-WT, myc-CARMA1-S649A, myc-CARMA1-S657A, or myc-CARMA1-S564A subcloned into MSCV-IRES-GFP retroviral vector. Culture supernatants were harvested, filtered using a 0.22-m filter, and incubated with the lymphoid cells lines in the presence of 8 g/ml polybrene. Cells were spinfected for 20 min at 800 ϫ g RPM. Depending on the experiment, cells were counted and analyzed for cell survival at 0 and 24 h posttransduction, or cultured and expanded for cell sorting based on GFP expression using a FACSAria cell sorter (BD Biosciences).
Cell stimulation, immunoprecipitation, and immunoblotting
DT40, Ramos, and Jurkat cells (2 ϫ 10 6 cell/condition) were stimulated with PMA (at doses ranging from 3.9 nM to 1 M) and ionomycin (at 1 g/ml), anti-IgM (at 5 g/ml), or anti-CD3/CD28 (at 10 g/ml/1 g/ml) for selected time points at 37°C. Cells were lysed in RIPA buffer (250 mM NaCl, 10 mM Tris-HCl (pH 7.4), 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 1 mM Na 3 VO 4 , 1 mM sodium fluoride) containing a mix of protease and phosphatase inhibitors (Sigma-Aldrich). For immunoprecipitations, 10 -30 ϫ 10 6 cells/condition were lysed in RIPA buffer without sodium deoxycholate and SDS. Lysates were incubated with 1.5 g of anti-myc for 15 min followed by 2 h incubation with protein G beads (GE Healthcare) at 4°C. For testing phospho-specific Abs, GST-PRD, GST-PRD-S649A, and GST-PRD-S657A recombinant proteins were produced and phosphorylated in vitro as described, using nonradioactive ATP (20) . To assess endogenous CARMA1 phosphorylation, purified splenic B cells (30 ϫ 10 6 cells/condition) from BALB/c or CARMA1 Ϫ/Ϫ mice were stimulated with P/I (1 M and 1 g/ml). CARMA1 was immunoprecipitated using protein A beads and 2 g of anti-CARMA1 Ab (Santa Cruz Biotechnology) overnight at 4°C. Protein complexes were resolved by SDS-PAGE and transferred to polyvinylidene fluoride membranes. Primary Abs were incubated overnight followed by 1-2 h of incubation with anti-rabbitIgG IRDye800 (Rockland), or anti-mouse IgG Alexa Fluor 680 (Molecular Probes). Proteins were detected and quantified by an Odyssey Infrared Imaging System from LI-COR Biosciences.
IKK in vitro kinase assay
DT40 cells (20 ϫ 10 6 cells/condition) were serum-starved for 1 h at 37°C and either left unstimulated or stimulated with P/I for 10 min at 37°C. Cells were lysed in ice-cold lysis buffer, and an IKK in vitro kinase assay (Cell Signaling Technology) was conducted as described by the manufacturer. (12), pRenilla-TK (Promega; transfection control) reporter vector, and several doses of myc-CARMA1 or myc-CARMA1-S649A, myc-CARMA1-S620A, or myc-CARMA1-S620/649A mutant cDNAs in the pIRES-PURO backbone (Clontech). At 6 h before harvesting, the cells were left unstimulated or stimulated with P/I (1 M/1 g/ml) for HEK 293 cells or CD3/CD28 (5 g/ml/1 g/ml) for Jurkat T cells. NF-B activation was analyzed measuring the firefly and Renilla luciferase activity according to the Dual-Luciferase Reporter assay from Promega.
NF-B reporter gene assays
Results
IKK and JNK activation in DT40 cells expressing CARMA1 phosphorylation site mutants
Using CARMA1-deficient chicken DT40 cell lines reconstituted with mutant chicken CARMA1 coding sequences, Shinohara et al. (22) were able to validate various potential PKC target sites in CARMA1 downstream of Ag receptor stimulation. We performed an identical set of experiments using P/I stimulation to confirm that the murine CARMA1 PKC target sites that we have previously identified (S564, S649, and S657 (20)), have the same effect on CARMA1 function as the correlating chicken CARMA1 residues. CARMA1
Ϫ/Ϫ DT40 cells were reconstituted with either CARMA1-WT or CARMA1 constructs with S564A, S649A, or S657A mutations. IKK and JNK activation was analyzed after treatment with a high dose of the Ag receptor chemical mimetics P/I (1 M/1 g/ml, respectively) ( Fig. 1) . JNK activity was assessed using phospho-JNK specific Abs, and IKK activity was assessed using an in vitro kinase assay.
Mutation of all three murine serine residues that we have reported to be PKC-specific substrates (CARMA1-3-mut) produced a CARMA1 molecule unable to reconstitute IKK or JNK activation, indicating that some of these residues are required to initiate CARMA1 signaling. To determine the impact of the individual residues, CARMA1 Ϫ/Ϫ DT40 cells expressing CARMA1 single serine mutants were activated and analyzed as described. Consistent with previous reports (19, 20, 22) , although S564A and S657A mutations substantially decreased both JNK (Fig. 1A, top) and IKK (Fig. 1B, top) activation, S649A mutation did not show any apparent defect under these activation conditions.
Phosphorylation of CARMA1 at S649 negatively regulates IKK activation
We consistently observed that, following stable transduction of CARMA1 Ϫ/Ϫ DT40 cells using retroviral vectors, protein expression levels of myc-CARMA1-S649A were ϳ3-to 5-fold lower than expression levels observed for WT myc-CARMA1, or myc-CARMA1 with other serine mutations (Fig. 1) . Shinohara et al. (22) reported a similar phenomenon with the analogous serine residue in the chicken CARMA1 sequence S660. Notably, despite its reduced expression level, myc-CARMA1-S649A reconstituted IKK and JNK activation to levels similar to that induced by the WT CARMA1 protein. This observation strongly suggested that the S649A mutation might enhance the signaling activity of CARMA1. When the levels of phospho-IB␣ and phospho-JNK in cells expressing myc-CARMA1-WT and myc-CARMA1-S649A were normalized to the CARMA1 expression levels (Fig. 1, A and B, bottom), we found that both phospho-IB␣ and phospho-JNK levels were increased ϳ3-to 4-fold in cells expressing myc-CARMA1-S649A over those induced by myc-CARMA1-WT.
Next we conducted dose-response assays of these plasmids, using various amounts of myc-tagged CARMA1 WT or S649A expression plasmids transiently transfected, along with constant amounts of NF-B-luciferase and TK-Renilla reporter plasmids, into Jurkat T cells followed by CD3/CD28 stimulation. CARMA1-S649A-transfected cells consistently exhibited a nearly 30 -50% increase in CD3/CD28-induced NF-B activation at 24 h posttransfection ( Fig. 2A) . The activity of the myc-CARMA1 and myc-CARMA1-S649A proteins was also evaluated in transiently transfected and P/I-stimulated 293T cells (Fig. 2B, bottom) . Comparison of NF-B reporter gene activation between various doses of myc-CARMA1 or myc-CARMA1-S649A expression vectors showed that myc-CARMA1-S649A-expressing cells consistently exhibited about 30% more NF-B activity than cells transfected with myc-CARMA1. Anti-myc immunoblotting (Fig. 2B , top) showed equivalent levels of WT and mutant protein expression in transfected cells, indicating that differential protein expression cannot account for these observed differences in NF-B activation. Of note, transient protein expression in Jurkat cells is difficult to measure due to their relatively low transfection efficiency. However, because we used identical plasmid preparations for reporter assays in both cell lines, our protein measurements in 293T cells are predicted to also reflect relative expression of these constructs in Jurkat T cells in Fig. 2A .
A recent study by Bidère et al. (24) showed that human CARMA1 activity was decreased by phosphorylation of S608, possibly by casein kinase 1␣ (CK1␣). To test whether mutation of this phosphorylation target in murine CARMA1 (S620, the murine analog of human S608) could additively or synergistically enhance down-regulation of CARMA1 activity with S649A, we compared the ability of CARMA1 with single serine mutants vs double mutant myc-CARMA1-S(620, 649)A to enhance NF-B reporter gene expression at 24 h posttransfection in Jurkat T cells (Fig. 2C) . The single mutant myc-CARMA1-S620A promoted enhanced NF-B activation to levels similar to that of myc-CARMA1-S649A. However, combining these individual serine mutations did not lead to an additive increase in NF-B reporter gene expression. The double mutant myc-CARMA1-S(620,649)A led to NF-B activity similar to that observed with the single serine mutants. These data suggest that CARMA1 activation status can be down-modulated by distinct phosphorylation events downstream of alternative signaling pathways (e.g., CK1␣ vs PKC) and imply that S620 and S649 phosphorylations are likely to target the same mechanism for CARMA1 down-regulation.
DT40 B cells expressing myc-CARMA1-S649A exhibit reduced growth and survival
Several alternative hypotheses could explain why the S649A mutation led to the observed reduction in CARMA1 expression levels in stably transduced cells. The S649A mutation may directly destabilize the CARMA1 protein; enhanced downstream signaling events may directly promote CARMA1 degradation; or cells that express higher levels of the S649A mutant may be counter-selected due to an alteration in cell growth parameters. As protein stability assays showed no difference in protein half-life between CARMA1 WT and S649A (see supplemental Fig. S1 ), 4 we elected to track the selection of ectopic CARMA1 expression in CARMA1 Ϫ/Ϫ DT40 B cells using an IRESdriven cis-linked GFP marker.
Cells were stably transduced using retroviral vectors expressing myc-CARMA1 or myc-CARMA1-S649A and FACS sorted to obtain 4 The online version of this article contains supplemental material. Ϫ/Ϫ DT40 cells stably expressing myc-CARMA1-WT, myc-CARMA1 (S564, S649, S657A) (3-mut), or the specified single serine-to-alanine mutants (2 ϫ 10 6 cells/condition) were activated with P/I (1 M and 1 g/ml, respectively) for the indicated time (A), or for 0 (Ϫ) and 10 (ϩ) min (B). JNK activation was assessed by immunoblotting using anti-phospho-JNK Abs (A), and IKK activity (measured as IB␣ phosphorylation) was analyzed (B) as described in Materials and Methods. Phospho-ERK immunoblot was used as an activation control, and anti-myc (CARMA1) and ERK blots were used as loading controls. Phosphorylation was detected using the phosphoserine Abs in whole cell lysates (WCL). Graphs below each blot show the quantification of the phospho-IB␣ and phospho-JNK levels normalized to expression of myc-CARMA1-WT or myc-CARMA1-S649A. Relative values at t ϭ 0 were set as 1.
homogeneous GFP-positive populations. In vivo selection was subsequently visualized by flow cytometric analysis of GFP at multiple time points after sorting (Fig. 3A) . WT myc-CARMA1-expressing cells exhibited a progressive increase in relative GFP expression over a 25-day culture period (Fig. 3A) . In contrast, DT40 cells expressing myc-CARMA1-S649A exhibited counter-selection leading to lower GFP expression levels including, ultimately, outgrowth of GFP null populations at later cell passages (Fig. 3A) .
Counter-selection results from cell growth or survival deficits secondary to the expressed transgene. To determine whether CARMA1 S649A expression led to decreased cell growth, survival, or both, CARMA1
Ϫ/Ϫ DT40 cells stably expressing myc-CARMA1, myc-CARMA1-S649A, or myc-CARMA1-S657A were cultured at identical initial cell numbers (2 ϫ 10 5 cells/ ml), and their growth was tracked by counting cell numbers at various time points over 72 h (Fig. 3B) . Cell populations expressing myc-CARMA1-S649A consistently exhibited reduced cell growth with a ϳ2-fold lower cell count at each time point analyzed. Similarly, cells expressing myc-CARMA1-S649A exhibited a delay of nearly 4 h in doubling time as compared with myc-CARMA1-or myc-CARMA1-S657A-expressing cells (Fig. 3B, right) . Additionally, we consistently observed that myc-CARMA1-S649A-expressing cells showed a modest but significant increase in basal cell death as assessed by forward and side light scatter analysis (Fig. 3C) .
Supporting these observations, experiments were also performed in CARMA1 Ϫ/Ϫ DT40 cells acutely transduced with freshly prepared retrovirus expressing either empty vector, myc-CARMA1, or myc-CARMA1-S649A, and survival and cell numbers were analyzed at 0 and 24 h posttransduction (Fig.  3D) . Although cells transduced with the empty vector or myc-CARMA1 showed similar cell numbers and viability after 24 h, cells transduced with myc-CARMA1-S649A failed to increase in cell number and exhibited a concomitant ϳ30% change in dead cells as assessed by either flow cytometry or trypan blue exclusion (Fig. 3D) . Thus, reduced cell survival, leading to counter-selection against myc-CARMA1-S649A, likely accounts for the lower expression levels of this protein mutant in avian DT40 B cell lines.
Increased JNK signaling in B cell lines expressing the CARMA1-S649A mutant
JNK signals have been implicated in the induction of cell death in DT40 B cells, and also in the reduction of cell growth in many other cell types (25, 26) . As it is well documented that CARMA1 activation induces both NF-B and JNK activation in B and T cells (7, 8, 22) , we hypothesized that the myc-CARMA1-S649A mutation enhanced JNK activation. To test this idea, we directly evaluated JNK phosphorylation in CARMA1 Ϫ/Ϫ DT40 B cells (Fig. 4) . In our initial studies, we did not detect differences in JNK activation in myc-CARMA1-vs myc-CARMA1-S649A-expressing cells using 1 M of PMA (Fig. 1) , likely a result of signal saturation. Thus for these studies, we stimulated CARMA1 Ϫ/Ϫ DT40 cells stably expressing either myc-CARMA1, myc-CARMA1-S649A, or empty vector using a range of PMA doses and a fixed ionomycin dose (Fig. 4) . As shown in Fig. 4A , whereas JNK phosphorylation was absent in vector-transduced CARMA1
Ϫ/Ϫ DT40 cells, cells expressing myc-CARMA1 or the myc-CARMA1-S649A mutant exhibited reconstituted JNK phosphorylation. The myc-CARMA1-S649A-expressing cells, however, consistently exhibited higher phospho-JNK levels than WT expressing cells (Fig. 4A) ; increased activity was observed even at the lowest PMA doses tested. In contrast, both cell populations showed similar levels of ERK phosphorylation, implying that this altered activity was specific to JNK signaling. To determine whether these events also occurred following direct Ag receptor stimulation, CARMA1 Ϫ/Ϫ DT40 B cells expressing myc-CARMA1-WT vs myc-CARMA1-S649A were activated with anti-chicken IgM (5 g/ml) for specific time points, and phospho-JNK levels were assessed by immunoblotting (Fig. 4B) . Under these conditions, cells expressing the myc-CARMA1-S649A mutant exhibited more rapid and slightly enhanced JNK activation (peaking at 5 min) compared with myc-CARMA1 (peaking at 15 min), although these differences were more subtle than P/I-driven responses. To determine whether these findings were relevant to mammalian B cells, the human B cell line (Ramos) was identically transduced and activated with low P/I doses (Fig. 4C) . Consistent with the results using DT40 cells, JNK phosphorylation was significantly increased in Ramos cells expressing myc-CARMA1-S649A compared with that induced by myc-CARMA1-expressing cells; relative ERK phosphorylation remained indistinguishable between the cell lines. When JNK phosphorylation levels were quantified in relation to CARMA1 expression levels, JNK phosphorylation was consistently ϳ2-to 3-fold higher in myc-CARMA1-S649A than JNK phosphorylation levels in myc-CARMA1-expressing cells (Fig. 4, bottom panels) .
Analysis of CARMA1 phosphorylation in vivo using phosphoserine-specific Abs
To understand whether S649 has a physiologically relevant regulatory role in the Ag receptor signaling cascade, we directly assessed whether it was indeed phosphorylated in response to Ag receptor or P/I stimulation in vivo. We generated polyclonal Abs against phospho-S649, as well as phospho-S657 as a positive control (analogous to chicken S668 (22) ) to measure in vivo phosphorylation of these residues. To verify their specificity, the resulting Abs were first used to immunoblot bacterially expressed CARMA1 PRD protein fragments with and without in vitro phosphorylation by recombinant PKC␤. As shown in Fig. 5A , both Abs reacted only with the phosphorylated WT-PRD, and not with unphosphorylated WT or with phosphorylated PRDs with serine-toalanine mutations at S649 or S657, respectively.
To analyze the phosphorylation of S649 and S657 downstream of Ag receptor signals in vivo, lymphoid cell lines including B cell (CARMA1 Ϫ/Ϫ DT40 and human Ramos B cells) and T cell (Jurkat) lines were retrovirally transduced to stably express myc-CARMA1 or myc-CARMA1 containing specific mutations of these serine residues. Cells were then stimulated with P/I (Fig. 5, B-D) , or Ag receptorspecific Abs (Fig. 5, E and F) . CARMA1 phosphorylation was detected by Western blotting using the phosphoserine Abs in either whole cell lysates in CARMA1 Ϫ/Ϫ DT40 cells (Fig. 5, B and F) or in myc-immunoprecipitates (Fig. 5, C , E, and F, myc-IP). P/I stimulation induced phosphorylation of the two serine residues with distinct kinetics in both B cell lines. Although phospho-S657 was rapidly induced, showing a maximum peak at 2-5 min poststimulation and a steady reduction at later time points, phospho-S649 was delayed but more sustained, reaching a maximum at 15-30 min poststimulation. Similarly, we analyzed these phosphorylation events induced by Ag receptor signaling in B and T cells lines (Fig. 5, E and F) . Anti-IgM in DT40 CARMA1 Ϫ/Ϫ B cells or anti-CD3/CD28 in Jurkat T cells induced phospho-S657 and phospho-S649 with almost identical kinetics to that induced by P/I Abs. We also determined that endogenous CARMA1 was phosphorylated at residue S649 after P/I stimulation in primary B lymphocytes (Fig. 5G) . These findings further support the physiological occurrence of this phosphorylation event.
Due to the substantial disparity between the kinetics of S649 and S657 phosphorylation, we investigated whether there was a hierarchical dependence of phosphorylation between these and other serine Ϫ/Ϫ DT40 cells stably expressing myc-CARMA1 (WT) or CARMA1-S649A were FACS sorted to obtain populations expressing homogenous, high levels of the IRES-driven cis-marker GFP. Cells were subsequently cultured at 37°C and 5% CO 2 for 25 days in standard medium (RPMI 1640 plus 10% FCS, 1% chicken serum, and supplements). Cells were collected at the indicated time points and GFP levels analyzed by flow cytometry. Histograms show successive time points. Untransduced refers to cells untreated with retrovirus. B, GFP-sorted myc-CARMA1-, myc-CARMA1-S649A-, or S657A-expressing CARMA1 Ϫ/Ϫ DT40 cells were cultured at 2 ϫ 10 5 cells/ml for 0 -72 h. Cells were harvested at the indicated time points and counted using a hemocytometer. Line graph shows show cell number (10 6 ) vs time in hours. Doubling time analyses is shown (right) for myc-CARMA1-vs myc-CARMA1-S649A-or myc-CARMA1-S657A-expressing cells calculated using the logarithmic least squares fitting technique (http://www.doubling-time.com). Data are mean Ϯ SEM for three independent experiments. C, Percentage of dead cells was analyzed using forward and side scatter analysis, and dead cells were gated in dot plots as indi- residues. Phosphorylation of CARMA1 with single serine-to-alanine mutations of S649 or S657 was tested in P/I-stimulated cells. Constructs with S564A mutations were also included in the analysis, as S564 is also required for NF-B activation in lymphocytes (20) . As shown in Fig. 5D , phosphorylation of either S649 or S657 was each unaffected by the absence of the other serine residues, indicating that phosphorylation of these individual residues can occur independently from each other. Ϫ/Ϫ DT40 cells expressing myc-CARMA1 or myc-CARMA1-S649A were left unstimulated or were stimulated with 5 g/ml IgM for the indicated time points. CARMA1 activity was assessed by phospho-JNK immunoblotting from 2 ϫ 10 6 cells/condition in whole cell lysate (WCL). C, Ramos human B cells stably expressing myc-CARMA1, myc-CARMA1-S649A, or empty vector (1 ϫ 10 6 cells/condition) were unstimulated or stimulated with the indicated doses of PMA and 1 g/ml ionomycin for 15 min at 37°C. Whole cell lysates were immunoblotted as described in A. A-C, Phospho-ERK, ERK, and myc (CARMA1) blots were used as activation and loading controls. Band density of JNK phosphorylation was quantified and expressed relative to those of the protein loading control myc-CARMA1; time point t ϭ 0 was set as 1 and used to normalize phospho-JNK levels from stimulated cells. Graphs in A and C show mean Ϯ SEM from three independent experiments. Student's t test was used to compare JNK activation between cells expressing CARMA1 vs CARMA1-S649A. ‫,ء‬ p Յ 0.05. FIGURE 5. CARMA1 residues S649 and S657 exhibit differential phosphorylation kinetics as detected by phospho-specific polyclonal Abs. A, GST-PRD, GST-PRD-S649A, and GST-PRD-S657A purified from recombinant bacteria were incubated with or without purified PKC␤ in the presence of diacyl glycerol, calcium, and nonradiolabeled ATP. In vitro phosphorylation of S649 and S657 was detected by immunoblotting using phospho-specific Abs. B, CARMA1 Ϫ/Ϫ DT40 cells stably expressing myc-CARMA1 were stimulated with P/I (1 M and 1 g/ml, respectively) for the indicated time points. Cells were lysed with RIPA buffer, and lysates resolved by SDS-PAGE. Phospho-S649 and phospho-S657 levels (right) relative to myc-CARMA1 levels in P/I-stimulated DT40 cells were shown. Data represent mean Ϯ SD of four independent experiments. C, Ramos B cells (15 ϫ 10 6 cells/condition) were stimulated with P/I as in B for the indicated time points. CARMA1 was immunoprecipitated using anti-myc Abs (myc-IP). D, CARMA1 Ϫ/Ϫ DT40 cells (2 ϫ 10 6 cells/condition) expressing myc-CARMA1 or myc-CARMA1 with single mutations (S649A, S657A, and S564A) were stimulated with P/I for the indicated time points and lysed with RIPA buffer. Lysates were resolved by SDS-PAGE. E and F, CARMA1 Ϫ/Ϫ DT40 cells (E) and Jurkat T cells (F) stably expressing myc-CARMA1 were activated for the indicated time points with anti-IgM (5 g/ml) or anti-CD3/CD28 (10 g/ml/1 g/ml), respectively (25-30 ϫ 10 6 cells/condition). CARMA1 was immunoprecipitated from the resulting cell lysates using anti-myc Abs (myc-IP), followed by SDS-PAGE. G, Primary splenic B cells were purified from WT or CARMA1 Ϫ/Ϫ mice, serum starved, stimulated for 10 min with or without P/I, and lysed. CARMA1 was immunoprecipitated using a polyclonal anti-CARMA1 Ab, and phospho-S649 was detected in the immunoprecipitated complexes. Quantification of phospho-S649 (bottom) is shown, and values were obtained relative to immunoprecipitated CARMA1. Time point t ϭ 0 was set as 1. B-G, Proteins from whole cell lysates (WCL) or lysates immunoprecipitated using anti-myc Abs were transferred to polyvinylidene fluoride membranes, and phospho-S649, phospho-S657, and myc-CARMA1 were detected by immunoblotting.
Requirement for PKC activity in CARMA1 phosphorylation at S649 and S657
Previous studies have shown that CARMA1 phosphorylation, detected in cells lines using total anti-phosphoserine Abs or in vitro using radioactive phospho-labeling of bacterially expressed proteins, required the activity of specific PKC isoforms; PKC␤ (found in B cells) and PKC (in T cells) (19, 20, 23) . Nevertheless, whether phosphorylation of individual serine residues requires the exclusive activity of a particular PKC isoform or kinase in vivo has not been fully determined. It has been reported that chicken S668 (mouse S657) requires PKC␤ activity in DT40 B cell line (22) ; however, whether S649 phosphorylation requires the same kinase is unknown. To assess whether PKC␤ is essential for phosphorylation of both S649 and S657 in B cells, PKC␤ Ϫ/Ϫ DT40 cells stably expressing myc-CARMA1 were activated and CARMA1 phosphorylation was analyzed and compared with that observed in myc-CARMA1-reconstituted CARMA1
Ϫ/Ϫ DT40 cells (Fig. 6A) . As anticipated, both phospho-S657 and phospho-S649 were markedly reduced in PKC␤ Ϫ/Ϫ DT40 cells. However, although phospho-S657 was abolished in the PKC␤ Ϫ/Ϫ cells, a low level of phospho-S649 was clearly present at later time points. This result suggested that other kinases or alternative PKC isoforms may be involved in CARMA1 phosphorylation of S649. To test this hypothesis, CARMA1 Ϫ/Ϫ DT40 cells expressing myc-CARMA1 were preincubated with either a pan-PKC or a novel PKC inhibitor and subsequently stimulated with P/I (Fig. 6B) . Although the pan-PKC inhibitor abrogated both phospho-S657 and phospho-S649, the novel PKC inhibitor (Rottlerin) exhibited no effect on phospho-S657 but partially decreased phospho-S649, indicating that although PKC␤ is the major effector for CARMA1 phosphorylation and activation in B cells, other kinases (likely including novel PKC isoforms) also participate in S649 phosphorylation.
Discussion
The current study clearly demonstrates that S649 is an in vivo kinase target downstream of Ag receptor engagement, and that loss of this serine has a positive effect on CARMA1 activity, as measured by both IKK activation and JNK phosphorylation. Thus, in the WT protein, phosphorylation at S649 likely results in CARMA1 down-regulation. These events were conserved in both chicken and human B cell lines, as well as in a human T cell line. Aided by the generation of polyclonal phospho-specific Abs, we found that S649 was phosphorylated in lymphocytes with a distinct kinetic pattern upon cell stimulation. Although the CARMA1-activating phosphorylation at S657 occurs rapidly and is transitory (Fig. 5 and Ref. 22) , the inhibitory phosphorylation at S649 is both delayed and more sustained. Interestingly, our data also show that phosphorylation of CARMA1 does not follow a hierarchical process. Phosphorylation of S649 occurred independently of phosphorylation at other residues including S564 and S657 (Fig. 5) . As PKC␤ and PKC are implicated in both rapid, activating phosphorylation and later-occurring deactivating phosphorylation (Fig. 5) , the mechanism governing the selective phosphorylation kinetics remains to be determined.
It is well established that PKC isoforms may have both positive and negative regulatory effects on Ag receptor signaling in lymphocytes (27, 28) . Additionally, it is well established that signaling proteins can be targeted by multiple kinases that may either positively or negatively affect the target protein activity. For example, Src protein tyrosine kinases and the Tec family kinase Btk are activated by specific tyrosine kinases, and deactivated by other serine/threonine kinases (29, 30) . In this study, we demonstrate that CARMA1 activation is both positively and negatively regulated by at least three independent, PKC-mediated phosphorylation events in the PRD induced by Ag receptor cross-linking (and by signals that mimic Ag receptor engagement) in B and T cell lines. In B cells, PKC␤ is required for S657 phosphorylation and is a major kinase targeting S649 (Fig. 6) . However, we observed that the phospho-S649 signal is partially intact in the absence of PKC␤. Because Rottlerin, an inhibitor of novel PKCs, partially blocked phospho-S649 (but not phospho-S657), we suggest that a novel PKC isoform may also contribute to the phosphorylation of CARMA1 at residue S649 in B cells. Interestingly, previous studies have shown that genetic deletion of the novel PKC isoform PKC␦, which is expressed in B cells, results in B cell hyperactivation and increased proliferation, which under tolerogenic conditions leads to increased NF-B and JNK activation upon antigenic stimulation (31, 32) Further investigation will be required to determine whether PKC␦, or another kinase, has a role in this phenotype.
It is well established that, although PKC␤/ phosphorylation is required for CARMA1 activity, other pathways can target CARMA1 phosphorylation, influencing the strength of its signal. Ϫ/Ϫ and PKC-␤ Ϫ/Ϫ DT40 cells stably expressing myc-CARMA1 (2 ϫ 10 6 cells/condition) were stimulated with P/I (1 M and 1 g/ml, respectively) for the indicated time points. B, CARMA1
Ϫ/Ϫ DT40 cell expressing myc-CARMA1 (2 ϫ 10 6 cells/condition) were preincubated with 5 M Rottlerin (novel PKC inhibitor), Ro318425 (general PKC inhibitor), or DMSO (vehicle) and stimulated with P/I for the indicated time points. Phospho-S649, phospho-S657, myc-CARMA1, phospho-ERK, and ERK were assessed by immunoblot. Graphs show the amount of phospho-S649 relative to myc using whole cell lysates (WCL).
Other kinases that have been shown to target CARMA1 (both within and outside of the PRD) include IKK␤, CK1␣, and calmodulin-dependent protein kinase II (22, 24, 33) (Fig. 7B) . Interestingly, Bidère et al. (24) have shown that although CK1␣ promotes CARMA1 activation, it also functions as a negative regulator of CARMA1-dependent NF-B activation. CK1␣ can phosphorylate S608 in human CARMA1 in vitro, and this modification is suggested to trigger CARMA1 degradation in vivo. In contrast, although a constitutively active mutant of CARMA1 underwent rapid turnover in DT40 cells, the basal stability of CARMA1 S649A was similar to that of the wild-type protein (see supplemental Fig. S1) . 4 This suggests that other negative regulatory events may be enhanced by this phosphorylation. Surprisingly, S620 and S649 phosphorylation also do not additively increase CARMA1 activation (Fig. 2) . Although in vivo phosphorylation of S608/620 (human/mouse, respectively) by CK1␣ remains to be directly demonstrated, together these data suggest that at least two alternative phosphorylation events (at S620 or S649) can mediate down-regulation of CARMA1 signaling, and imply these signals promote negative regulation via a similar pathway.
Although significant, phospho-S649 down-regulation of CARMA1 activity was incomplete, and was most evident when low doses of activators were used. We hypothesize that phospho-S649 may set a threshold for Ag receptor-driven IKK and JNK activation. We expect that additional signaling events are likely to be required to fully turn off the CARMA1 signal. Indeed, other negative regulatory processes that have been shown to deactivate the CARMA1 signalosome as a whole include Bcl-10 degradation (34 -37), deubiquitination of substrates including MALT1 and TRAFs by A20 (or CYLD) (38 -40) , and direct CARMA1 ubiquitination and degradation (M.M.-G., K.S., and D.R., manuscript submitted). Furthermore, phosphorylation of some activating residues in CARMA1 is rapid and transitory (Fig. 5) , possibly suggesting involvement of a phosphatase in CARMA1 inactivation.
Genetic knockout models in mice have demonstrated that loss of CARMA1 has no effect on early stages of lymphocyte development. However, CARMA1 is required for the development of B1 cells, for maintenance of mature B2 B cells, and for Ag receptor signaling of both B and T cells (6 -9) . Although it is not known whether overactive or allelic variants of CARMA1 have any role in pathologies of early B cells, there is mounting evidence to suggest that CARMA1 signaling enhances B cell lymphomagenesis in humans (41, 42) . A subset of poor prognosis, ABC-DLBCL (activated B cell-like diffuse large B cell lymphomas) requires basal CARMA1 expression and activity to promote NF-B activation and survival (42) . Furthermore, mutations in the coiled-coil domain of CARMA1, which produces a constitutive active CARMA1 molecule, have been described in nearly 10% of these ABC-DLBCL. At first glance, our finding that expression of the overactive CARMA1-S649A mutant is counter-selected (due to increased cell death) in CARMA1 Ϫ/Ϫ DT40 B cells appears to contradict these earlier findings. We hypothesize that because CARMA1 activates both NF-B (associated with cell survival programs) and JNK (associated with apoptotic programs), overactive CARMA1 may differentially affect specific lymphocyte populations depending on their differentiation stage and on the relative influence these distinct pathways have on their growth and survival. Ag receptor-stimulated immature B cells undergo cell growth arrest and apoptosis, whereas more mature cells (such as the ABC-DLBCL) respond with the opposite biological outcome (43, 44) . The DT40 cell line represents an immature B cell stage, and both BCR stimulation and JNK activation are strongly linked with apoptosis in this cell line (45) . Additionally, although DT40 cells constitutively activate NF-B, they down-regulate their BCR over time, indicating a counter-selection for the Ag receptor pathway. Taken together, the results presented here further support the idea that the survival and growth of B lymphoma cells, chicken DT40 cells in this case, are sensitive to the activation status of CARMA1.
In summary, the data presented in this study, combined with previous work, suggest the following working model for CARMA1 activation and subsequent deactivation via specific phosphorylation signals (Fig. 7) . In resting cells, most CARMA1 is maintained in an inactive closed-conformation (Fig. 7A) . Ag receptor stimulation activates PKC␤ or PKC in B or T cells, respectively (as well as other kinase pathways), leading to rapid phosphorylation at specific residues including, most notably, S657 (Fig. 7A, left) and S564 in murine CARMA1. These modifications promote interactions with critical proteins (including Bcl-10, Ag recognition promotes PKC␤ and PKC activation in B and T cells, respectively. These PKC isoforms (and probably other kinases including CK1␣, calmodulin-dependent protein kinase II, or IKK␤) rapidly phosphorylate CARMA1 (2-5 min) at specific residues, thereby releasing conformational interference (left). This conformational change promotes CARMA1 activation and interaction with Bcl-10 and MALT1 and subsequent activation of the IKK and JNK signaling cascades (middle). Reaching maximum phosphorylation levels between 15 and 30 min postactivation, other residues including S649, and likely S620, are phosphorylated by classical or novel PKC isoforms and CK1␣, respectively (right). These later phosphorylation events negatively regulate CARMA1 activation. B, Schematic showing the location of the activating and inactivating phosphorylation sites and candidate enzymes that regulate their modification. Mouse (m-), human (h-), and chicken (ch-) sites are presented. Residues (underlined) indicate the phosphorylation sites that have been directly demonstrated in vivo.
MALT1, and others) involved in both IKK and JNK activation (Fig. 7A, middle) . Although these activation events occur early in the activation of CARMA1, a delayed wave of PKC␤/-dependent, and possibly PKC-␦-or CK1␣-dependent phosphorylation, targets residues S649 and possibly S620. These latter and sustained events down-regulate CARMA1-dependent NF-B and JNK activation through currently unknown mechanisms that include limiting Bcl-10 and MALT1 interaction, reducing CARMA1 oligomerization or plasma membrane recruitment, or possibly controlling CARMA1 turnover (Fig. 7A, right) . As it is apparent that multiple phosphorylation signals regulate the extent of CARMA1 activation and deactivation (Fig. 7B) , it will be important to more fully elucidate the kinase targets in CARMA1 and the mechanisms controlling CARMA1 down-regulation, to understand how the lymphocyte fine tunes its response to antigenic challenges.
